ProCE Banner Activity

Pharmacists Discuss Practical Considerations and Novel Treatment Options for Patients With Myelofibrosis

Clinical Thought

In this commentary, expert pharmacists discuss best practices in managing patients with myelofibrosis and review novel therapeutic approaches, including treatment following first-line JAK inhibitor failure.

Released: July 31, 2023

Share

Faculty

Justin Arnall

Justin Arnall, PharmD, BCOP

Clinical Coordinator, Hematology
Specialty Pharmacy Service, Atrium Health
Charlotte, North Carolina
Assistant Professor of Clinical Education
Division of Practice Advancement and Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Victoria R. Nachar

Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist
Hematology
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC and the Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner

Supporters

Supported by an educational grant from GSK.

GSK

Partners

Clinical Care Options, LLC

ProCE Banner

Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner

Faculty Disclosure

Primary Author

Justin Arnall, PharmD, BCOP

Clinical Coordinator, Hematology
Specialty Pharmacy Service, Atrium Health
Charlotte, North Carolina
Assistant Professor of Clinical Education
Division of Practice Advancement and Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina

Justin Arnall, PharmD, BCOP: consultant/advisor/speaker: CTI, HEMA, Novo Nordisk.

Victoria R. Nachar, PharmD, BCOP

Clinical Pharmacist Specialist
Hematology
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.